Clinical trials: QTc Interval
Healthy Volunteers
Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects
This is a single-center, randomized, partially double-blind, placebo and active-controlled, 4-period crossover design thorough QT/QTc (TQT) clinical study to evaluate the effects of ziresovir on cardiac repolarization in healthy…
- Trial name
- NCT06591845
- Testing
- Ziresovir 125 mg, Ziresovir 500 mg, Moxifloxacin hydrochloride tablet 400 mg
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Anaemia
Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers
This study is being performed to comply with regulatory requirements that all new non-antiarrhythmic drugs must be assessed for potential effects on cardiac repolarization through electrocardiographic evaluation in a 'Thorough…
- Trial name
- NCT02293148
- Testing
- GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers, Healthy
A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers
This is a partially double-blind study in healthy adult subjects, which will be conducted as a placebo- and active-controlled, single-dose, crossover study.
- Trial name
- NCT03164109
- Testing
- GC4419 IV, Oral moxifloxacin
- Where
- Australia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Galera Therapeutics, Inc.
Healthy
A TQT Study of Effect of M2951 on Cardiac Repolarization
The purpose of this study is to assess potential effects of M2951 on cardiac repolarization (i.e. prolongation of QT interval).
- Trial name
- NCT07214935
- Testing
- Moxifloxacin, M2951 Low Dose, M2951 High Dose
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
ECG, Pharmacokinetics
Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML
This is a single-arm, open-label, Phase 4 study evaluating the effect of GO on the QTc, pharmacokinetics, safety, and immunogenicity of GO as a single-agent monotherapy in adult and pediatric patients with relapsed or refractory…
- Conditions
- ECG, Pharmacokinetics, Safety
- Trial name
- NCT03727750
- Testing
- Gemtuzumab Ozogamicin
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 51 people
- Sponsor
- Pfizer
Healthy Participants
A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants
This study will assess the effect of single oral doses of baxdrostat on the ECG interval measured from the onset of the QRS complex to the end of the T wave (QT) interval corrected for HR using Fridericia's formula (QTcF)…
- Trial name
- NCT06194032
- Testing
- Baxdrostat, Moxifloxacin
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
ANX-188 Thorough QT/QTc Study in Healthy Volunteers
This study has been designed in compliance with the ICH-E14 guideline (2005) to evaluate the effect of ANX-188 at therapeutic and supratherapeutic concentrations on cardiac repolarization, specifically, Fridericia's QT-Interval…
- Trial name
- NCT01790087
- Testing
- ANX-188 Therapeutic Dose, ANX-188 Supratherapeutic dose, Saline
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Mast Therapeutics, Inc.
Evaluation of QTc Interval
An Open-Label, Single-Center Study to Evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc at Steady State Following Once-daily Administration of CASSIPA® in Opioid Dependent Subjects.
The objective of this study is to evaluate the exposure-response relationship between the steady-state plasma concentrations of buprenorphine, norbuprenorphine, naloxone, and total naloxone and the change from baseline in QTc…
- Trial name
- NCT04088266
- Testing
- 16 mg buprenorphine with 4 mg naloxone sublingual film
- Sponsor
- Teva Pharmaceuticals USA
Malaria, Falciparum
Safety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy Volunteers
The aim of such a study is to evaluate the impact of a therapeutic dose of Eurartesim™ compared to Riamet®, after multiple dose administration for 3 days in healthy male and female subjects on electrocardiographic parameters.
- Trial name
- NCT01103830
- Testing
- Eurartesim™, Riamet®
- Where
- France
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- sigma-tau i.f.r. S.p.A.
Advanced Solid Tumor
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
Study 516-010 is an open-label Phase 1, drug-drug interaction and QTc study evaluating the effect of sitravatinib on probe substrates for CYP450 enzymes and BCRP and P-gp transporters.
- Trial name
- NCT04887194
- Testing
- Sitravatinib, Warfarin, Dextromethorphan
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mirati Therapeutics Inc.
HIV Infections
A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients
This open-label study will evaluate the safety, pharmacokinetics and antiviral activity of a modified Invirase (saquinavir)/ritonavir regimen in treatment-naïve HIV-1 infected patients.
- Trial name
- NCT01638650
- Testing
- Nucleoside Reverse Transcriptase Inhibitor (NRTIs), ritonavir, saquinavir [Invirase]
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Healthy Participants
Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
This is a single-center, 2-part (Part A and Part B) study in healthy participants. Part A (Dose Finding) is an open-label, SAD study to identify the dose for Part B.
- Trial name
- NCT05924815
- Testing
- Aficamten, Moxifloxacin
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Cytokinetics
Prolonged QTc Interval, Pharmacokinetic
Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects
The objective of this study was to evaluate the effects of cebranopadol (GRT6005) on the electrical activity of the heart in healthy participants.
- Trial name
- NCT03958123
- Testing
- 100 μg cebranopadol, 200 μg cebranopadol, 400 μg cebranopadol
- Where
- United States
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects
The purpose of this study is to evaluate the effects on QTc interval in healthy males when administered a single dose of NKTR-118 compared with placebo and moxifloxacin.
- Trial name
- NCT01325415
- Testing
- NKTR-118, moxifloxacin
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hepatitis C
TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers
The purpose of this study is to evaluate the effect of TMC435 on the results of electrocardiograms (ECGs) in healthy volunteers. An electrocardiogram is an electric recording of the heart.
- Trial name
- NCT01269294
- Testing
- TMC435, Moxifloxacin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Healthy Volunteers - Male and Female
A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults
This is a Phase 1, single-center, randomized, single-blind (participants are blinded), placebo controlled, four-way cross over TQT study (4×4 Williams square design) to investigate the effect of KP-001 on the QTc interval using…
- Trial name
- NCT06649942
- Testing
- KP-001, Moxifloxacin 400 mg
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kaken Pharmaceutical
Cancer
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
This study will estimate the effect of lapatinib on cardiac repolarization (QTc interval duration) in subjects with advanced solid tumors.
- Trial name
- NCT01328054
- Testing
- lapatinib
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart
This study is being performed to investigate the potential for AZD5672 to affect the electrical conduction pathways in the heart.
- Trial name
- NCT00887770
- Testing
- AZD5672, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Myelofibrosis
QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants
Primary Objective: To evaluate the effect of single-dose TQ05105 on QTcF interval in healthy Chinese participants. Secondary Objectives: To evaluate the effects of single-dose TQ05105 on other cardiac parameters (heart rate, QT…
- Trial name
- NCT07708272
- Testing
- TQ05105 tablets, Moxifloxacin Hydrochloride Tablets
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Solid Tumors
Effect of Tivantinib on the QTC Interval in Cancer Subjects
The purpose of this study is to determine the effects of tivantinib on the QTc interval in patients with solid tumors
- Trial name
- NCT01699061
- Testing
- Tivantinib
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Daiichi Sankyo